Combination therapy before surgery for head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of targeted immunotherapy and chemotherapy given before surgery or radiation for head and neck cancer. The goal is to shrink the tumor and potentially improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with head and neck squamous cell carcinoma (a type of cancer) that is stage III or IVa (locally advanced).
- You have not had any treatment for this cancer yet.
- You have never had immunotherapy (drugs that help your immune system fight cancer) before.
- You are in generally good health (able to do daily activities) and do not have major heart, liver, kidney, or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (benmelstobart and anlotinib) given with standard chemotherapy before surgery in people with advanced mouth cancer. The goal is to see if this combination can shrink the tumor and improve the chance of successful treatment.
This trial tests a new combination of two drugs (one targeted therapy and one immunotherapy) plus standard chemotherapy before surgery for head and neck cancer. The goal is to see if this approach can shrink tumors and improve outcomes.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a combination of an immunotherapy drug (tirelizumab) with two chemotherapy drugs before surgery for head and neck cancer that has spread to lymph nodes. The goal is to shrink the tumor and improve treatment outcomes.
This trial tests a new immunotherapy drug (adelbelimab) combined with chemotherapy given before surgery, for people with head and neck cancer. The goal is to see if this combination can shrink the tumor and improve the chances of successful surgery.
This study tests a drug called pabliximab (an immunotherapy) given before surgery to shrink head and neck tumors. It aims to make surgery more effective and may improve outcomes for people with this cancer.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.